ES2378072T3 - Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur - Google Patents

Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur Download PDF

Info

Publication number
ES2378072T3
ES2378072T3 ES05738545T ES05738545T ES2378072T3 ES 2378072 T3 ES2378072 T3 ES 2378072T3 ES 05738545 T ES05738545 T ES 05738545T ES 05738545 T ES05738545 T ES 05738545T ES 2378072 T3 ES2378072 T3 ES 2378072T3
Authority
ES
Spain
Prior art keywords
tegafur
composition
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05738545T
Other languages
English (en)
Spanish (es)
Inventor
Takeshi Tahara
Hiroshi Ambe
Jun Kuritani
Naruo Nomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2378072T3 publication Critical patent/ES2378072T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES05738545T 2004-04-29 2005-04-27 Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur Expired - Lifetime ES2378072T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
US566180P 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (1)

Publication Number Publication Date
ES2378072T3 true ES2378072T3 (es) 2012-04-04

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05738545T Expired - Lifetime ES2378072T3 (es) 2004-04-29 2005-04-27 Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur

Country Status (16)

Country Link
US (1) US20080166427A1 (enExample)
EP (1) EP1750703B1 (enExample)
JP (1) JP5376758B2 (enExample)
AT (1) ATE540679T1 (enExample)
AU (1) AU2005237364B2 (enExample)
CY (2) CY1112451T1 (enExample)
DK (1) DK1750703T3 (enExample)
ES (1) ES2378072T3 (enExample)
HR (1) HRP20120293T1 (enExample)
ME (1) ME01335B (enExample)
PL (1) PL1750703T3 (enExample)
PT (1) PT1750703E (enExample)
RS (1) RS52217B (enExample)
RU (1) RU2348409C2 (enExample)
SI (1) SI1750703T1 (enExample)
WO (1) WO2005105086A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
BR112012000873A2 (pt) * 2009-07-17 2019-11-05 Myriad Genetics Inc método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2015227009B2 (en) * 2014-03-06 2019-10-31 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2015238170B2 (en) * 2014-03-28 2019-08-15 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
JP6364546B2 (ja) * 2015-04-30 2018-07-25 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
MX2022014094A (es) * 2020-05-19 2022-12-08 Cellix Bio Private Ltd Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
DE3585869D1 (de) * 1984-10-30 1992-05-21 Otsuka Pharma Co Ltd Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung.
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
DE69003670T2 (de) * 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
WO1992021345A1 (en) * 1991-05-27 1992-12-10 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Also Published As

Publication number Publication date
EP1750703B1 (en) 2012-01-11
US20080166427A1 (en) 2008-07-10
CY2012014I1 (el) 2016-04-13
RU2006142101A (ru) 2008-06-20
CY1112451T1 (el) 2015-12-09
HRP20120293T1 (hr) 2012-04-30
ME01335B (me) 2013-12-20
RU2348409C2 (ru) 2009-03-10
DK1750703T3 (da) 2012-05-07
EP1750703A1 (en) 2007-02-14
JP5376758B2 (ja) 2013-12-25
ATE540679T1 (de) 2012-01-15
AU2005237364A1 (en) 2005-11-10
JP2007534634A (ja) 2007-11-29
PL1750703T3 (pl) 2012-05-31
WO2005105086A1 (en) 2005-11-10
EP1750703A4 (en) 2008-02-27
SI1750703T1 (sl) 2012-02-29
CY2012014I2 (el) 2016-04-13
PT1750703E (pt) 2012-02-23
AU2005237364B2 (en) 2010-07-08
RS52217B (sr) 2012-10-31

Similar Documents

Publication Publication Date Title
RU2394581C2 (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
ES2378072T3 (es) Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US6503889B2 (en) Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
Hoff The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL and S-1: a Review of Their Clinical Development and Therapeutic Potential
US7799783B2 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CN104159589A (zh) 肝脏状况的治疗
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
JP2007534634A5 (enExample)
ES3026709T3 (en) Cancer treatment using docetaxel by controlling peak plasma levels
ES2926934T3 (es) Inhibidores de tirosina quinasa para uso en un método de tratar cáncer en asociación con una ingesta calórica reducida
Roviello et al. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination
JP2005513167A (ja) エポシロン誘導体と代謝拮抗剤からなる組合せ
Eng et al. Oral fluoropyrimidine treatment of colorectal cancer
WO2008109349A1 (en) Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
Scheulen et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
ES2348996T3 (es) Potenciador de radioterapia.
CN114650816A (zh) 用于治疗胆管癌的包含帕比司他的联合疗法
Choi et al. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
Fukushima S-1 review from preclinical pharmacology
Shirasaka et al. Preclinical and clinical practice of S-1 in Japan